Rhythm Pharmaceuticals, Inc. (RYTM)
| Market Cap | 6.06B +53.8% |
| Revenue (ttm) | 217.17M +58.7% |
| Net Income | -207.84M |
| EPS | -3.14 |
| Shares Out | 68.53M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 554,372 |
| Open | 87.65 |
| Previous Close | 87.66 |
| Day's Range | 87.65 - 90.16 |
| 52-Week Range | 60.70 - 122.20 |
| Beta | 1.92 |
| Analysts | Strong Buy |
| Price Target | 138.20 (+56.37%) |
| Earnings Date | May 5, 2026 |
About RYTM
Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases in the United States and internationally. The company’s lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, Bardet-Biedl and Alström syndrome, Prader-Willi syndrome, and hypothalamic obesity. It is in Phase 3 clinical trials for treating acquired hypothalamic... [Read more]
Financial Performance
In 2025, Rhythm Pharmaceuticals's revenue was $189.76 million, an increase of 45.83% compared to the previous year's $130.13 million. Losses were -$201.92 million, -23.68% less than in 2024.
Financial StatementsAnalyst Summary
According to 16 analysts, the average rating for RYTM stock is "Strong Buy." The 12-month stock price target is $138.2, which is an increase of 56.37% from the latest price.
News
Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026
-- Patients with PWS treated with setmelanotide therapy (N=17) achieved clinically meaningful BMI or BMI z-score reductions, reductions in fat mass with preservation of lean mass, and improvements in ...
Rhythm Pharmaceuticals to Announce Interim Six-Month Phase 2 Results Evaluating Setmelanotide in Patients with Prader-Willi Syndrome
BOSTON, June 12, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rar...
Rhythm Pharmaceuticals Transcript: Goldman Sachs 47th Annual Global Healthcare Conference 2026
Six-month data for Praloretel and updated RM-718 results will be presented at ENDO, while IMCIVREE's HO launch targets a 10,000-patient U.S. market with strong physician interest and high anticipated adherence. The pipeline includes both oral and injectable options, with a focus on rare diseases and a solid cash position for ongoing development.
Rhythm Pharmaceuticals Transcript: Jefferies Global Healthcare Conference 2026
IMCIVREE's U.S. HO launch shows strong early uptake and broad physician engagement, with international expansion and new clinical data on the horizon. Next-generation therapies are advancing, and market opportunities are expected to grow as diagnosis and awareness increase.
Rhythm Pharmaceuticals Announces Seven Abstracts Accepted for Presentation at ENDO 2026
BOSTON, May 29, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...
Rhythm Pharmaceuticals Proxy statement: Proxy filing
Rhythm Pharmaceuticals filed a proxy statement on May 29, 2026, providing details for shareholder voting and corporate governance matters.
Rhythm Pharmaceuticals Announces Publication of New Bardet-Biedl Syndrome Diagnostic Algorithm in the American Journal of Medical Genetics
BOSTON, May 28, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...
Rhythm Pharmaceuticals Announces Participation in Upcoming Investor Conferences
BOSTON, May 26, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...
Rhythm Pharmaceuticals Slides: Corporate presentation
Rhythm Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on May 26, 2026.
Rhythm Pharmaceuticals Transcript: Bank of America Global Healthcare Conference 2026
The company’s drug targets rare genetic and acquired obesity syndromes, with a recent HO launch showing strong early uptake and broad physician engagement. Next-generation therapies aim to improve convenience and reduce side effects, while ongoing studies in Prader-Willi syndrome may expand indications.
Rhythm Pharmaceuticals Announces New Data Presentations at the 2026 European Congress of Endocrinology
– Real world data showed clinically meaningful BMI reductions with setmelanotide in 62 adults with 12-month data living with acquired hypothalamic obesity (HO) in France –
Rhythm Pharmaceuticals price target raised to $143 from $140 at Canaccord
Canaccord raised the firm’s price target on Rhythm Pharmaceuticals (RYTM) to $143 from $140 and keeps a Buy rating on the shares. The firm said the company delivered a topline…
Rhythm Pharmaceuticals Announces Participation in Upcoming Bank of America Global Healthcare Conference
BOSTON, May 06, 2026 (GLOBE NEWSWIRE) -- Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a global commercial-stage biopharmaceutical company focused on transforming the lives of patients living with rare...
Rhythm Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 saw $60.1M in revenue, driven by BBS and a strong U.S. launch of IMCIVREE for acquired HO, with over 150 start forms and positive payer response. International expansion advanced with EU approval and Japan NDA filing, supporting a robust outlook for 2026.
Rhythm Pharmaceuticals Earnings release: Q1 2026
Rhythm Pharmaceuticals released its Q1 2026 earnings on May 5, 2026, summarizing the period's financial results.
Rhythm Pharmaceuticals Slides: Q1 2026
Rhythm Pharmaceuticals has posted slides in relation to its Q1 2026 quarterly earnings report, which was published on May 5, 2026.
Rhythm Pharmaceuticals Quarterly report: Q1 2026
Rhythm Pharmaceuticals has published its Q1 2026 quarterly earnings report on May 5, 2026.
Rhythm Pharmaceuticals Proxy statement: Proxy filing
Rhythm Pharmaceuticals filed a proxy statement on May 5, 2026, providing details for shareholder voting and corporate governance matters.
Rhythm Pharmaceuticals reports Q1 EPS (83c), consensus (86c)
Reports Q1 revenue $60.11M, consensus $56.07M. “The U.S and European approvals of IMCIVREE mark a transformational milestone for patients with acquired hypothalamic obesity who, until now, had no appr...
Rhythm Pharmaceuticals sees FY26 operating expenses $385M-$415M
Meeker added, “In addition, we continue to advance our MC4R agonism pipeline with upcoming data readouts from ongoing trials of setmelanotide in Prader-Willi syndrome and our weekly injectable, RM-718...
Rhythm Pharmaceuticals Reports First Quarter 2026 Financial Results and Business Update
-- IMCIVREE ® (setmelanotide) launched in the U.S. for acquired hypothalamic obesity; more than 150 patient start forms received in the first six weeks following FDA approval on March 19, 2026 -- -- F...
Rhythm Pharmaceuticals presents Phase 3 TRANSCEND trial data
Rhythm Pharmaceuticals (RYTM) announced the presentation of new data delivered by Rhythm and its partners at The Pediatric Endocrine Society Annual Meeting. “The data presented provide important longe...
Rhythm Pharmaceuticals Announces New Data Presentations in Acquired Hypothalamic Obesity at Pediatric Endocrine Society
-- Pediatric patients (n=10) with acquired hypothalamic obesity achieved sustained reductions in BMI and BMI-Z at 2.5 years of setmelanotide therapy -- -- Weight category improvements observed in pedi...
Rhythm Pharmaceuticals’ Imcivree granted MAA in Europe for obesity
Rhythm Pharmaceuticals (RYTM) announced the European Commission, or EC, has expanded the marketing authorization for Imcivree – setmelanotide – to include the treatment of obesity and control of hunge...
Rhythm Pharmaceuticals Announces IMCIVREE® (Setmelanotide) Granted Marketing Authorization by European Commission for the Treatment of Obesity and Control of Hunger in Patients with Acquired Hypothalamic Obesity
-- First therapy to be FDA-approved and EC-authorized for acquired hypothalamic obesity -- -- European Commission grants authorization in adults and children 4 years of age and above with acquired hyp...